Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1543408 | 0.84 | HPGD (0.50) | TSHRSMN1; SMN2RECQLGAACA12 | |
| SCHEMBL27714618 | 0.80 | MAOB (0.58) | MAOBTSHRSMN1; SMN2GAACA12 | |
| SCHEMBL1298904 | 0.74 | ALDH1A1 (0.40) | TSHRSMN1; SMN2GAAKMT2AMEN1 | |
| SCHEMBL4119956 | 0.73 | KDM4E (0.33) | TSHRSMN1; SMN2KMT2AMEN1KCNH2 | |
| Fumaric Acid SCHEMBL1300044 | 0.72 | ALDH1A1 (0.35) | SMN1; SMN2GAAKMT2AMEN1MAPT | |
| SCHEMBL28526673 | 0.71 | TSHR (0.49) | TSHRRECQLGAACA12CA1 | |
| SCHEMBL6972956 | 0.70 | CNR2 (0.40) | TSHRSMN1; SMN2GAAKMT2AMAPT | |
| SCHEMBL9248362 | 0.69 | EGFR (0.47) | TSHRSMN1; SMN2CA12CA1CA2 | |
| SCHEMBL12107936 | 0.69 | ALDH1A1 (0.36) | SMN1; SMN2GAAKMT2AMEN1MAPT | |
| SCHEMBL4115335 | 0.69 | ALDH1A1 (0.36) | SMN1; SMN2GAAKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273797-B2 | Treating renal cancer using 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-2-methyl-benzaldehyde | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273797-B2 | Treating renal cancer using 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-2-methyl-benzaldehyde | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273797-B2 | Treating renal cancer using 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-2-methyl-benzaldehyde | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-09-25 | — | — | US | disclosed |
| US-20110269840-A1 | TREATING RENAL CANCER USING A 4-[BIS[2-[(METHYLSULFONYL)OXY]ETHYL]AMINO]-2-METHYL-BENZALDEHYDE | HEALTH AND HUMAN SERVICES | 2011-11-03 | — | — | US | disclosed |
| US-20110269840-A1 | TREATING RENAL CANCER USING A 4-[BIS[2-[(METHYLSULFONYL)OXY]ETHYL]AMINO]-2-METHYL-BENZALDEHYDE | HEALTH AND HUMAN SERVICES | 2011-11-03 | — | — | US | disclosed |
| US-7989501-B2 | Treating renal cancer using a 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-benzaldehyde | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989501-B2 | Treating renal cancer using a 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-benzaldehyde | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090131536-A1 | Treating or Preventing Renal Cancer Using a Dimethane Sulfonate | GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131536-A1 | Treating or Preventing Renal Cancer Using a Dimethane Sulfonate | GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131536-A1 | Treating or Preventing Renal Cancer Using a Dimethane Sulfonate | GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2007044015-A9 | TREATING OR PREVENTING RENAL CANCER USING A DIMETHANE SULFONATE | US GOV HEALTH & HUMAN SERV (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007044015-A1 | TREATING OR PREVENTING RENAL CANCER USING A DIMETHANE SULFONATE | GOVERNEMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131536-A1 | Treating or Preventing Renal Cancer Using a Dimethane Sulfonate | VHL, DDX21, MGMT | MAOB 3466/4885TSHR 4527/4885SMN1; SMN2 1981/4885 |
| US-20110269840-A1 | TREATING RENAL CANCER USING A 4-[BIS[2-[(METHYLSULFONYL)OXY]ETHYL]AMINO]-2-METHYL-BENZALDEHYDE | GLS, MGMT, KDM5B | MAOB 1312/4885TSHR 4749/4885SMN1; SMN2 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.